Experimental Alzheimer's drug shows benefits in phase 3 trial, company says

  • 📰 NBCNewsHealth
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 51%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

Japanese drugmaker Eisai said cognitive function slowed over 18 months in patients who received the drug, called lecanemab.

BSIP / UIG via Getty ImagesThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.

Dr. Alberto Espay, a neurologist at the University of Cincinnati College of Medicine, said that the benefit was"small" and that it fell below the threshold of what would be meaningful to a patient. Still, he said,"patients can view this with cautious optimism."

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Can't wait for the one for cancer. You know the disease that insurance companies and hospitals make most their money on. Oh, wait the key word is money. So, no time soon for that one!

I know we all probably might have heard about Bitcoin but don't know how it works, I tried it in a week ago by a man who recommended me to Samantha_M078 on Twitter he guides me through and i made a return of $10500 after a week of trading, connect with her

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 707. in DE

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen